US Congress Senate Bill 3914 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on June 8 2020 - 25% progression, died in committee
Action: 2020-06-08 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Provides for Medicare coverage of medical devices that are approved under the Food and Drug Administration (FDA) Breakthrough Devices Program. (Under the program, manufacturers work with the FDA to expedite the review and approval of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions.) The bill allows designated medical breakthrough devices to be temporarily covered under Medicare during a three-year transitional period. The Centers for Medicare & Medicaid Services (CMS) must assign payment codes for such devices within three months of FDA approval. The CMS must also establish a process to allow for continued coverage after the transitional period has expired, taking into account any additional evidence or data the CMS deems necessary. The CMS must also provide for temporary and, where appropriate, permanent Medicare coverage of breakthrough devices for which there is no existing benefit category (i.e., classification).

Ensuring Patient Access to Critical Breakthrough Products Act of 2020

Sen. Martha McSally [R-AZ]

Date	Chamber	Action
2020-06-08	Senate	Read twice and referred to the Committee on Finance.

HB5333 (Related) 2019-12-09 - Referred to the Subcommittee on Health.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/3914/all-info
Text	https://www.congress.gov/116/bills/s3914/BILLS-116s3914is.pdf